Business Context and Reporting Period
Company: ICU Medical, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Business Overview: ICU Medical develops, manufactures, and markets disposable medical connection systems for intravenous (I.V.) therapy, primarily the CLAVE product line, designed to prevent needlestick injuries and infections. The company sells to distributors and medical product manufacturers, with a significant portion of revenue derived from a strategic relationship with Hospira, Inc.
Key Financial Metrics
| Metric (in thousands) | Q1 2005 | Q1 2004 |
|---|---|---|
| Total Revenue | $27,085 | $22,233 |
| Net Sales | $25,663 | $21,270 |
| Gross Profit | $15,225 | $12,420 |
| Gross Margin (on Net Sales) | 59.3% | 58.4% |
| Operating Income | $6,528 | $6,314 |
| Net Income | $4,417 | $4,140 |
| Diluted EPS | $0.30 | $0.28 |
| Cash & Cash Equivalents | $6,452 | $3,798 |
| Liquid Investments | $89,625 | $N/A |
| Total Cash & Investments | $96,077 | $N/A |
| Working Capital | $117,280 | $N/A |
| Debt | $0 | $0 |
Note: The filing does not provide a specific working capital figure for Q1 2004, though it notes an increase to $117.3 million in Q1 2005 from $109.6 million at year-end 2004. Liquid investments for Q1 2004 are not explicitly listed in the comparative balance sheet section provided in the text, though cash equivalents were $3,798.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 22% to $27.1 million, driven by a 25% increase in net sales. This was primarily due to increased unit shipments of CLAVE products to Hospira, which accounted for 75% of the CLAVE sales increase.
- Customer Concentration: Sales to Hospira, Inc. represented 61% of total revenue in Q1 2005, up from 60% in Q1 2004. Hospira sales increased to $16.4 million from $13.2 million.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 42% to $8.0 million. This increase was largely attributed to $1.5 million in legal fees related to patent lawsuits and $0.6 million in professional fees.
- Investment Income: Investment income increased 90% to $588,000, driven by higher yields and increased invested funds.
- Liquidity: Cash and liquid investments totaled $96.1 million, an increase of $8.7 million from the prior quarter, supported by strong operating cash flows of $7.9 million.
Guidance, Outlook, and Risks
Subsequent Event: Hospira Agreement
On May 1, 2005, ICU Medical acquired Hospira's Salt Lake City manufacturing facility for approximately $32.1 million in cash. Simultaneously, a 20-year Manufacturing, Commercialization and Development Agreement (MCDA) became effective. Under this agreement, ICU Medical will produce critical care products (catheters, angiography kits) exclusively for Hospira. Management estimates sales under this agreement will approximate $45 million in 2005, though with "only small profits" initially.
Outlook and Guidance
- Gross Margins: Expected to be in the 53-55% range for the remainder of 2005, excluding the impact of the new MCDA, which is expected to significantly reduce gross margins initially.
- Expenses: SG&A costs are expected to be comparable to or lower than 2004 levels for the remainder of the year, excluding the MCDA impact, due to reduced patent litigation costs and lower Sarbanes-Oxley compliance expenses.
- Capital Expenditures: Estimated at $5.0 million for the remainder of 2005 (excluding the Hospira facility purchase), totaling approximately $6.2 million for the year.
Risk Factors
- Customer Dependence: Heavy reliance on Hospira (61% of revenue). Any deterioration in this relationship or Hospira's market position could materially harm the company.
- Product Concentration: CLAVE products accounted for 58% of revenue in Q1 2005 (75% including custom I.V. systems). Declines in CLAVE sales would significantly impact profitability.
- Competition and Pricing: Intense competition from larger firms and potential price erosion. The company has reduced prices to maintain market share.
- Patent Litigation: Ongoing litigation against Alaris Medical Systems (Cardinal Health) regarding patent infringement. Failure to enforce patents could lead to market share loss.
- Interest Rate Sensitivity: The company holds significant cash and liquid investments ($96.1 million). Continued low interest rates could adversely affect investment income.
Investor Verification Checklist
- Hospira Relationship Stability: Verify the terms and long-term security of the new MCDA and the strategic supply agreement with Hospira, given the 61% revenue concentration.
- MCDA Profitability: Monitor the actual gross margins and profitability of the new Salt Lake City facility operations, as management expects "small profits" in 2005.
- Patent Litigation Status: Track the outcome of the lawsuit against Alaris Medical Systems, as a loss could impact future CLAVE sales and pricing power.
- CLAVE Product Lifecycle: Assess the competitive landscape for needleless connectors to ensure the CLAVE product does not face obsolescence or significant price erosion.
- Capital Allocation: Review the impact of the $32.1 million cash outlay for the Hospira facility on future liquidity and working capital requirements.